Schering-Plough Corporation bought the 45% of its majority-owned China JV, Shanghai Schering-Plough Pharmaceutical, that it did not already own. Its former partners, Shanghai Pharmaceutical Group and Shanghai Pharmaceutical Industry Corporation, put the 45% stake up for sale in May, saying they wanted to streamline their business into fewer subsidiaries. At the time, the two companies were asking 66.3 million RMB ($9.6 million) for their stake. Schering-Plough did not disclose the final price. More details...

Stock Symbol: (NYSE: SGP)